Cargando…
PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53
BACKGROUND: The aim of this study was to explore the efficacy and define mechanisms of action of PRIMA-1(MET) as a TP53 targeted therapy in soft-tissue sarcoma (STS) cells. METHODS: We investigated effects of PRIMA-1(MET) on apoptosis, cell cycle, and induction of oxidative stress and autophagy in a...
Autores principales: | Grellety, Thomas, Laroche-Clary, Audrey, Chaire, Vanessa, Lagarde, Pauline, Chibon, Frédéric, Neuville, Agnes, Italiano, Antoine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604610/ https://www.ncbi.nlm.nih.gov/pubmed/26463477 http://dx.doi.org/10.1186/s12885-015-1667-1 |
Ejemplares similares
-
Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin
por: Laroche, Audrey, et al.
Publicado: (2015) -
ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status
por: Laroche-Clary, Audrey, et al.
Publicado: (2020) -
BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
por: Laroche-Clary, A, et al.
Publicado: (2015) -
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017) -
Prognostic impact of circulating tumor cells in patients with soft‐tissue sarcomas: a prospective study
por: Blanchi, Julie, et al.
Publicado: (2023)